Inhibition of ADAM9 promotes the selective degradation of KRAS and sensitizes pancreatic cancers to chemotherapy.
Huang YK, Cheng WC, Kuo TT, Yang JC, Wu YC, Wu HH, Lo CC, Hsieh CY, Wong SC, Lu CH, Wu WL, Liu SJ, Li YC, Lin CC, Shen CN, Hung MC, Lin JT, Yeh CC, Sher YP.
Huang YK, et al. Among authors: wu hh, wu wl, wu yc.
Nat Cancer. 2024 Mar;5(3):400-419. doi: 10.1038/s43018-023-00720-x. Epub 2024 Jan 24.
Nat Cancer. 2024.
PMID: 38267627